Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke

Zhai, Mingfeng; Cao, Shugang; Yang, Jinwei; Cao, Xin; Zhao, Dong; Liu, Wanyin; Fu, Yat Pang; Guan, Qing; Wang, Yu; Liu, Hongbo

doi:10.1007/s40120-023-00488-3

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stroke is a leading cause of morbidity, mortality, and long-term disability worldwide [ 41 , 42 ]. Alteplase is currently the only intravenous thrombolytic drug that is FDA approved, but its low recanalization rate, high risk of ICH, and short half-life necessitate continuous intravenous infusion.…”

Section: Discussionmentioning

confidence: 99%

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

Introduction In recent years, as one of the drugs for the treatment of acute ischemic stroke (AIS), the clinical application of tenecteplase is still controversial. Therefore, we aimed to evaluate the safety and efficacy of tenecteplase versus alteplase to guide clinical practice. Methods A search of PubMed, MEDLINE, EMBASE, Cochrane Library, and Web of Science databases until February 15, 2023 was conducted to identify eligible articles. The quality of the included studies was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 and Stata 17 were used to perform the meta-analysis and detect publication bias, and risk ratios (RRs) with 95% confidence intervals (95% CIs) were reported for each outcome measure. Results A total of 1326 records were retrieved in this meta-analysis. As a result of the limited reports on tenecteplase in patients with AIS and the lack of high-quality randomized controlled trials (RCTs), and considering the impact of publication bias, we did not include any of these studies published before 2015. Ultimately we included 16 RCTs with a total of 7508 patients, including 3940 patients treated with alteplase and 3568 patients treated with tenecteplase. Tenecteplase was associated with better early neurological improvement (RR 0.10; 95% CI 0.00–0.19; P = 0.04), recanalization of blood vessels (RR 0.24; 95% CI 0.07–0.40; P = 0.01), and 90-day excellent neurological recovery (RR 0.12; 95% CI 0.01–0.24; P = 0.04). In addition, there were no significant differences in other efficacy and safety outcomes between the two groups. The funnel plot and Begg’s as well as Egger’s tests showed no significant publication bias. Conclusions This meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.

show abstract

Section: Discussionmentioning

confidence: 99%